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OBJECTIVES: To determine the safety of intramyocardial injection of autologous bone marrow cells in patients undergoing 
surgical myocardial revascularization (CABG) for severe coronary artery disease.
INTRODUCTION: There is little data available regarding the safety profile of autologous bone marrow cells injected during surgical 
myocardial revascularization. Potential risks include arrythmias, fibrosis in the injected sites and growth of non-cardiac tissues.
METHODS: Ten patients (eight men) were enrolled; they were 59±5 years old with limiting angina and were non-optimal can-
didates for complete CABG. Bone marrow cells (1.3±0.3x108) were obtained prior to surgery, and the lymphomonocytic fraction 
(CD34+=1.8±0.3%) was separated by density gradient centrifugation. During surgery, bone marrow cells were injected in non-
grafted areas of ischemic myocardium. During the first year after surgery, the patients underwent laboratory tests, cardiac imaging, 
and 24-hour ECG monitoring.
RESULTS: Injected segments: inferior (n=7), anterior (n=2), septal (n=1), apical (n=1), and lateral (n=1) walls. Except for a 
transient elevation of C-reactive protein at one month post-surgery (P=0.01), laboratory tests results were within normal ranges; 
neither complex arrhythmias nor structural abnormalities were detected during follow-up. There was a reduction in functional class 
of angina from 3.6±0.8 (baseline) to 1.2±0.4 (one year) (P<0.0001). Also, patients had a significant decrease in the ischemic score 
assessed by magnetic resonance, not only globally from 0.65±0.14 (baseline) to 0.17±0.05 (one year) (P=0.002), but also in the 
injected areas from 1.11±0.20 (baseline) to 0.34±0.13 (one year) (P=0.0009).
CONCLUSIONS: Intramyocardial injection of bone marrow cells combined with CABG appears to be safe. Theoretical concerns 
with arrhythmias and/or structural abnormalities after cell therapy were not confirmed in this safety trial.
KEY WORDS: Cells. Cardiac surgery. Angiogenesis. Angina. Ischemia. 
INTRODUCTION
Cell therapy represents a novel therapeutic strategy for 
treating cardiovascular diseases including ischemic heart dis-
ease (IHD) and heart failure.1,2 It is widely accepted that bone 
marrow-derived cells (BMC) can play a role in the induction 
of angiogenesis under different conditions such as wound 
healing and limb ischemia,3,4 post-myocardial infarction,5,6 and 
endothelization of vascular grafts.7 Results from animal models 
of IHD have shown that pluripotent stem cells have the potential 
to differentiate in both contractile and blood vessels in ischemic 
tissues.8,9 Early reports of improvement in myocardial perfusion 
and segmental contractility either for acute10 or chronic11 IHD 
in small series of patients have established the feasibility and 
short-term safety of transplantation of BMC in IHD.208
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Still, the long-term safety profile of BMC in the clinical 
setting is subject to several major concerns.12 Since BMC 
consist of a heterogeneous population of undifferentiated 
cells able to differentiate into various cell types by means of 
a complex and poorly understood process, it is possible that 
unintended cell differentiation towards non-cardiac tissues 
may occur13 as well as oncogenic transformation.14. Uncon-
trolled vascular growth has been demonstrated in transgenic 
animals expressing increased levels of angiogenic cytok-
ines,15 a finding inspiring caution since BMC can express 
different angiogenic factors.16 Based on previous data on the 
use of myoblasts in cell therapy trials, malignant ventricular 
arrhythmias have been documented with potentially serious 
consequences.17,18 These safety issues must be carefully ad-
dressed before progressing to efficacy studies with a larger 
number of patients. 
Accordingly, the present study was designed to test the 
hypothesis that, in the long-term, intramyocardial injection 
of autologous BMC is feasible, safe and well-tolerated. Fur-
thermore, this injection may serve as an adjunctive therapy 
to patients undergoing surgical myocardial revascularization 
for severe IHD and diffuse coronary artery disease (CAD), 
helping to increase myocardial perfusion and contractility.
METHODS
This prospective, non-randomized, open-label, phase 
I clinical study was approved by the Institutional Ethics 
Committee and was conducted in accordance with federal 
guidelines of the Brazilian National Research Ethics Council 
(CONEP).
Patient Selection
From August 2002 to July 2003, ten patients were re-
ferred to the Cell Therapy Group for Chronic Ischemic Heart 
Disease at the Heart Institute (InCor) for clinical evaluation. 
They were included in this safety trial based on the follow-
ing criteria: the age was between 18 and 80 years; limiting 
angina was present (Class III-IV as defined by the Canadian 
Cardiovascular Society19 despite maximally tolerated medi-
cal therapy); multi-vessel CAD was present; patients were 
non-optimal candidates for a “complete” bypass surgery 
due to the extension and severity of the obstructive lesions 
according to an expert panel; and patients had at least one 
non-bypassable coronary artery associated with an area of 
viable, ischemic myocardium. Patients were excluded if any 
of the following criteria was met: life expectancy less than 
one year; past or current history of neoplasia; no objective 
evidence of myocardial ischemia; primary hematological dis-
ease; or associated cardiomyopathy of other etiologies. All 
patients provided a signed, written informed consent. Table 
1 shows the clinical characteristics of enrolled patients.
Study Protocol
At baseline (B), and at 1, 3, 6, and 12 months after the 
procedure, all patients were subjected to a clinical evalua-
tion, laboratory tests, 24-h Holter monitoring, and echocar-
diogram. Also, myocardial perfusion was blindly assessed 
by magnetic resonance imaging (MRI). After the first year, 
patients were followed on a clinical basis only. A five-year 
follow-up re-evaluation is currently being performed.
• 24-h Holter Monitoring
ECG Holter monitoring was performed with Marquette 
800 portable amplitude-modulated two-channel devices 
(Marquette 9428; Marquette Medical Systems, Milwau-
kee, WI). After the monitor was withdrawn, the tapes were 
analyzed with the MARS system (Marquette). Maximum, 
minimum, and mean heart rate values were determined, and 
the occurrence of arrhythmias was recorded.
• Echocardiogram
Echocardiogram examinations were performed by two-
dimensional (2-D) imaging and by spectral and color flow 
mapping with a 2.75-MHz transducer or a 2–4-MHz/3–5-
MHz phased array transducer as previously described20 with 
an Apogee CX 200 ultrasound system (Interspec, Inc, Ambler, 
PA), or with an HDI 3000/5000 device (Advanced Technology 
Laboratories, Bothell, WA). The left ventricle (LV) ejection 
fraction was determined by the 2-D mode from the apical 
view (4- and 2-chamber), according to Simpson’s rule.
• Magnetic Resonance Imaging (MRI)
All patients underwent MRI examination in a 1.5T MR 
scanner (GE CV/i System, GE Medical Systems, Wakesha, 
WI). First-pass myocardial perfusion LV short-axis images 
were obtained 3 min after dipyridamole injection (0.56mg.
Table 1 - Clinical characteristics of enrolled patients.
Variable Patients (n=10)
Age (years) 59±5
Male / female (n) 8 / 2
Diabetes (n) 7
Hypertension (n) 10
Hypercholesterolemia (n) 8
Current or previous smoker (n) 6
Previous myocardial infarction (n) 5
Previous myocardial revascularization (PCI/CABG) (n) 7209
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kg-1 injected over 4 min). After dynamic MR images acquisi-
tion was started, 0.05mM.kg-1 of gadolinium-based contrast 
material (gadodiamide, Ominiscan, Amersham Health, 
Princeton, NJ) was injected into the antecubital vein by a 
power injector at a rate of 5mL.s-1 and followed by a 20-mL 
saline flush. Immediately after this stress perfusion sequence, 
aminophyline was intravenously injected. Myocardial perfu-
sion was blindly determined in 17 myocardial segments; 
each segment was graded as normal perfusion (score 0), or 
having mild (score 1) or severe (score 2) perfusion defects. 
An overall ischemic score based on all 17 segments (total 
ischemic score) or only segments injected with BMC (re-
gional ischemic score) was calculated.
Preparation of the BMC
After induction of anesthesia and immediately prior to 
surgery, 100 mL of bone marrow from the right posterior iliac 
crest were aspirated and heparinized. Bone marrow–derived 
progenitor and mononuclear cells were isolated by density 
gradient centrifugation on Ficoll-Paque Plus (Amersham 
Biosciences Corp., Piscataway, NJ), washed with heparinized 
saline, resuspended in 5mL normal saline, and placed in five 
1-mL syringes ready for injection. A 1-mL sample of the cell 
suspension was used for cell counting and sorting by flow 
cytometry using leukocyte differentiation markers. A trypan 
blue exclusion test showed viability greater than 90%.
• Flow Cytometry Analysis
The cell sample consisted of a heterogeneous cell popula-
tion with bone marrow–derived progenitor and mononuclear 
cells. The samples were treated with human IgG polyclonal 
antibody and incubated with the different monoclonal 
antibodies conjugated with fluorescein isothiocyanate 
(Pharmingen, San Diego, CA), phycoerythrin (PE), PerCP 
or CyChrome as shown in Table 2.21
Erythrocytes were lysed after staining with BD lysis 
buffer solution according to the manufacturer’s instruc-
tions. Data acquisition and analyses were performed on a 
three-color immunofluorescent FACS with CellQuest 3.1 
software (BD).
Injection of BMC During Surgical Myocardial 
Revascularization
CABG was done during cardiopulmonary bypass and 
warm blood cardioplegic arrest as previously described.22 
Once all bypasses had been completed, 25 samples of cell 
suspension (0.2 mL) were injected into the ischemic non-
bypassable area of myocardium, using a 22-gauge hypoder-
mic needle (Figure 1). Afterwards, the heart was reperfused, 
and the operation completed as usual.
Statistical Analysis
Data analyses were performed with a commercially 
available statistical package (JMP for Windows – version 
6.0.0, SAS Institute Inc., Cary, NC). Results for continuous 
variables are presented as mean±SD, and for categorical 
variables as percentages. One-way ANOVA with repeated 
measurements was used for comparison between time points. 
Statistical significance was set at P<0.05.
Table 2 - Flow cytometry markers.21
Antibody Main cellular expression Manufacturer
Anti-CD3 (clone HI3a) Thymocytes, T cells Pharmingen
Anti-CD4 (clone MT310) Thymocyte subsets, helper and inflammatory T cells (about two thirds of periph-
eral T cells), monocytes, macrophages
Pharmingen
Anti-CD8 (clone DK250 Thymocyte subsets, cytotoxic T cells (about one third of peripheral T cells) Pharmingen
Anti-CD10 (clone HI10a) B and T cell precursors, bone marrow stromal cells Becton, Dickinson & Co
Anti-CD13 (clone WM-47) Myelomonocytic cells Dako North America
Anti-CD14 (clone TUK-4) Myelomonocytic cells Pharmingen
Anti-CD15 (clone BI59) Neutrophils, eosinophils, monocytes Pharmingen
Anti-CD19 (clone HD-37) B cells Pharmingen
Anti-CD31 (clone L133.1) Monocytes, platelets, granulocytes, B cells, endothelial cells Becton, Dickinson & Co
Anti-CD34 (clone HPCA-2) Hematopoietic precursors, capillary endothelium Becton, Dickinson & Co
Anti-CD38 (clone HB27) Early B and T cells, activated T cells, germinal center B cells, plasma cells Becton, Dickinson & Co
Anti-CD45 (clone 2D1) All hematopoietic cells Becton, Dickinson & Co
Anti-CD56 (clone BI59) Natural killer cells Pharmingen
Anti-CD133 (clone AC141) Stem/progenitor cells Miltenyi Biotech Inc210
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RESULTS
Procedural Data
The total operation time for CABG (including the in-
tramyocardial injections of BMC) was 6h27min±1h25min; 
the “on-pump” time was 1h04min±15min. Patients had 
4.1±1.7 coronary arteries with stenosis greater than 70% and 
they received 2.6±0.2 grafts. 
Injected myocardial segments (n=12) included the in-
ferior (n=7), anterior (n=2), septal (n=1), apical (n=1) and 
lateral (n=1) walls. Note that in two patients, more than one 
myocardial segment was injected with BMC.
The number of cells injected per patient was 1.3±0.3x108. 
The fractions of CD34+ and CD133+ cells were 1.50±0.15% 
and 0.67±0.65%, respectively. A more detailed analysis of 
the cell population subtypes can be seen in Table 3.
Clinical Morbidity and Mortality
The mean in-hospital stay after surgery was 11±2 days. 
In-hospital non-fatal complications included pulmonary 
infection (n=2) and acute decompensation of heart failure 
(n=1), all of which were managed clinically and completely 
resolved after a few days. There were no deaths related to 
the procedure and all patients were discharged for follow-up 
at the out-patient clinic.
All patients completed the pre-specified first year of 
follow-up; no complications were recorded. During this 
period, the angina functional class levels significantly de-
creased from 3.6±0.8 (baseline) to 1.2±0.4 (12 months) (P 
< 0.0001).
 
Laboratory Tests
Results of main biochemical/hematological tests are 
shown in Table 4. We observed a significant elevation of 
C-reactive protein at one month after surgery compared to 
baseline, but this value returned to the normal range in the 
following evaluations. No other hematological abnormalities, 
including liver or renal dysfunction, were observed. 
Cardiac Arrhythmias
The mean heart rate (HR) and the number of supraven-
tricular or ventricular premature beats are shown in Table 5. 
During follow-up, no patient presented life-threatening ar-
rhythmias such as sustained ventricular tachycardia (VT).
Echocardiogram
No structural abnormalities were seen on Doppler 
echocardiograms for any time point after the procedure: no 
pericardial effusion, no fibrosis at injection sites, and no 
growth of non-cardiac tissues. At 12 months after surgery, 
LV function analysis showed that, compared to baseline, 
there was no significant change in either the mean LV end-
systolic volume (73±7 vs. 68±10mL; P=0.41) or the mean 
end-diastolic volume (149±10 vs. 136±13mL; P=0.47) 
Figure 1 - Intramyocardial injection of autologous bone marrow cells during 
CABG in non-bypassable areas of ischemic, viable myocardium.
Table 3 - Selected cell populations (%) after flow cytom-
etry.
Cell Population Phenotype % of Injected Cells
CD34+ 1.50±0.15
CD45+ CD133+ 0.7±0.1
CD45- CD133+ 0.04±0.01
CD14+ 6.6±0.8
CD19+ 4.0±0.5
CD4+ 9.1±1.1
CD8+ 5.7±0.7
CD31+ 2.2±0.3211
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(Table 6). Overall, there was no significant change in the 
mean LV ejection fraction (0.54±0.03 vs. 0.52±0.03; P=0.68) 
compared to baseline. 
Magnetic Resonance Imaging (MRI)
As seen in Figure 2, the LV ischemic score decreased 
significantly during the first year (panel A) as expected after 
a myocardial revascularization procedure. More interestingly, 
however, there was also an early and sustained improvement 
in myocardial perfusion in injected non-revascularized areas 
compared to baseline (panel B). No structural abnormalities 
were seen on the MRI after the procedure.
DISCUSSION
The results presented here show the feasibility and long-
term safety of intramyocardial injection of autologous BMC 
combined with surgical myocardial revascularization in 
patients suffering from diffuse CAD, who were not optimal 
candidates for a complete surgical bypass procedure. More-
over, injected BMC might have contributed to increased tis-
sue perfusion in areas of ischemic myocardium not suitable 
for direct revascularization.
The majority of patients with mild to moderate angina 
can be adequately treated with anti-anginal medications.23 
However, as life expectancy increases and the mortality 
Table 4 - Selected laboratory tests at baseline and during the first year of follow-up.
Variable Baseline 1 m 3 m 6 m 12 m P
Hemoglobin (g/dL) 13.9±1.5 12.0±1.3 13.6±1.3 13.4±2.1 13.2±1.9 0.12
White cells (x103/mm3) 7.6±1.9 7.0±1.7 7.1±2.3 6.7±1.5 6.5±1.6 0.67
Platelets (x103/mm3) 230±57 271±144 231±46 236±79 191±78 0.39
Urea (mg/dL) 42±14 44±12 37±13 39±15 44±13 0.80
Creatinine (mg/dL) 1.2±0.3 1.2±0.6 1.1±0.2 1.2±0.5 1.2±0.5 0.92
AST 12±6 10±4 10±2 10±3 10±3 0.55
ALT 16±11 19±5 11±2 11±5 11±4 0.44
Glucose level (mg/dL) 113±34 124±39 113±19 111±29 137±48 0.43
Total cholesterol (mg/dL) 184±36 154±29 165±27 177±32 167±29 0.25
HDL-cholesterol (mg/dL) 43±7 37±5 40±5 40±5 45±6 0.02
LDL-cholesterol (mg/dL) 106±24 84±24 93±29 92±38 93±21 0.57
Triglycerides (mg/dL) 178±89 167±58 157±51 179±65 133±46 0.47
C-reactive protein (mg/dL) 0.1±0.1 4.0±3.5 0.2±0.1 0.2±0.1 0.4±0.5 0.01
INR 1.0±0.1 1.1±0.1 1.1±0.1 1.0±0.1 1.0±0.1 0.80
Table 5 - Data from 24-h ECG monitoring (Holter) at baseline and during the first year of follow-up.
Variable Baseline 1 m 3 m 6m 12m P
Mean heart rate (bpm/min) 73±10 75±12 79±17 74±11 74±12 0.88
Ventricular premature beats/h 6±13 5±9 8±17 34±6 6±9 0.58
Supraventricular premature beats/h 3±4 7±11 2±2 4±9 15±35 0.55
Table 6 - Echocardiography data at baseline and during the first year of follow-up.
Variable Baseline 1 m 3 m 6m 12m P
Septum (mm) 10±1 10±1 10±1 10±1 9±2 0.28
Posterior wall (mm) 10±1 9±1 10±1 10±1 9±1 0.39
LV end-diastolic diameter (mm) 51±7 55±6 53±5 53±5 53±9 0.94
LV ejection fraction (%) 63±14 66±8 58±13 61±8 67±13 0.80
Left atrium (mm) 41±8 40±3 40±2 42±1 38±5 0.62
Aorta (mm) 32±3 32±3 32±4 32±3 28±9 0.58212
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rate due to acute coronary syndromes decreases, there is a 
growing population of patients with CAD for whom medical 
therapy is only partially effective. New therapeutic strategies 
are necessary, since many of them have already undergone 
multiple PCIs or surgical revascularization and hence, are 
not “ideal” candidates for additional procedures. 
Deprivation of oxygen and nutrients to myocytes in 
chronic IHD may lead to death of viable myocardium and 
cell replacement by fibrous tissue deposition, which further 
impairs LV function. Neoangiogenesis, a multifactorial pro-
cess involving complex interactions between inflammatory 
cells, cytokines, and many extracellular matrix proteins, is 
a crucial step in preserving cardiomyocytes from death.24 
Usually, when extensive myocardial ischemic injury occurs, 
the contribution of neoangiogenesis to the ischemic capillary 
network is insufficient to keep pace with tissue demands; 
therefore, normal contractility of ischemic, but viable, myo-
cardium cannot be sustained.25
Experimental evidence suggests that BMC have the 
potential to induce therapeutic angiogenesis in ischemic 
tissues.26 After vascular injury, endothelial progenitor cells 
are naturally mobilized from the bone marrow to the circula-
tion, along with hematopoietic stem cells and hematopoietic 
progenitor cells. The physiological role of co-recruitment 
of hematopoietic stem and progenitor cells in formation 
of long-lasting functional neovessels remains to be deter-
mined.27
Based on the initial reports of successful transplantation 
of progenitor cells in patients with acute or chronic coronary 
artery disease,9-11 we conducted this phase I, open-label, non-
randomized trial and were able to show that intramyocardial 
injection of autologous BMC combined with surgical myo-
cardial revascularization is feasible, safe and well-tolerated. 
However, our data suggest a role for injected BMC in in-
creasing myocardial perfusion.
Regarding safety issues within the first year after this 
procedure, early complications included pulmonary infec-
tion and decompensation of heart failure, conditions most 
likely related to the surgical procedure itself rather than the 
cell injections per se. One of the most disturbing complica-
tions related to cell therapy, based on previous experience 
with myoblasts, is the occurrence of malignant arrhythmias. 
Fortunately, there was no detectable increase in the number 
of supraventricular or ventricular premature beats and no 
life-threatening arrhythmias were detected. 
Except for a transient elevation of C-reactive protein 
early in the follow-up after surgery, all other biochemical 
and hematological values were within the normal range. 
Again, since CRP is a marker of inflammation, its elevation 
is no surprise after a major surgery like CABG. Cardiac im-
aging studies showed no evidence of scar tissue formation 
in the injection sites, no evidence of structural abnormalities 
related to the procedure such as pericardial effusion, and no 
evidence of in situ growth of non-cardiac tissues.
Overall, there was no overall appreciable change in LV 
ejection fraction or end-diastolic/systolic volumes. One can 
assume that since the mean LV function was within the normal 
range, no significant improvement would be seen in an already 
normal LV function. Nevertheless, specifically in patients with 
low LV ejection fraction, LV function increased significantly 
after surgery (data not shown), reflecting the functional recov-
ery of ischemic viable (hibernating) myocardium.
Although this was basically a safety trial, we performed 
a myocardial perfusion assessment in an attempt to collect 
preliminary data on the efficacy of stem cell therapy for 
severe CAD. MRI results showed a significant decrease in 
the LV ischemic score after the procedure; this decrease was 
not only in the total ischemic score (as expected), but also 
in the injected, non-revascularized areas. These data suggest 
an improvement in myocardial perfusion in the injected but 
non-grafted areas. Even though an indirect effect for this im-
provement from the grafts placed in the adjacent areas cannot 
be ruled out, it is tempting to speculate that the transplanted 
Figure 2 - Total (A) and regional (B) LV ischemic scores as assessed by MRI 
at baseline and during the first year after injection of BMC.213
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cells may have contributed to this response. In a study similar 
to ours, Stamm et al.28 injected BMC into the infarct border 
zone in six patients who had had a myocardial infarction and 
undergone CABG. Their work showed that, as of three to 
nine months after surgery, LV function was enhanced in four 
patients, and infarct tissue perfusion had improved strikingly 
in five patients. More recently,29 the same group extended their 
initial series of patients and concluded that, at least for the first 
three years of follow-up, intramyocardial delivery of purified 
bone marrow stem cells together with CABG surgery is safe 
and provides beneficial effects.
In summary, we were able to show that, during the first 
year of a four year follow-up, intramyocardial injection 
of BMC appears to be safe and may have contributed to 
increased myocardial perfusion in the ischemic, non-revas-
cularized myocardium. The effectiveness of cell transplanta-
tion in improving myocardial perfusion and contractility in 
patients with advanced CAD is a question to be addressed 
in controlled, randomized studies with a larger series of 
patients and longer follow-up. Cell transplantation has been 
addressed in recent studies, albeit with conflicting results.30,31 
A much larger, multicenter, randomized, double-blind, 
placebo-controlled study is underway.32
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